Clinical Trial Update: Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase III trial update planning to compare the investigational GFH375 against standard chemotherapy in KRAS G12D-mutant metastatic pancreatic cancer; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• GFH375 (GFH375)

Snippet

Sponsor: Genfleet Therapeutics (Shanghai) Inc. | Conditions: Metastatic Pancreatic Cancer | Phase 3 | Status: NOT_YET_RECRUITING